CAR-T疗法在实体肿瘤领域获重大进展,科济药业盘中涨超20%

第一财经
30 Dec 2024

12月30日早间,科济药业(02171.HK)宣布,舒瑞基奥仑赛注射液用于治疗晚期胃/食管胃结合部腺癌的中国关键II期临床试验取得初步阳性结果。  消息公布后,科济药业当日股价盘中大涨超20%,当日收盘时报9.03港元/股,涨7.63%。  公告显示,该试验是一项在中国进行的随机对照、多中心的临床试验,旨在评估舒瑞基奥仑赛注射液(CT041)治疗Claudin18.2表达阳性、既往接受过至少2线...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10